

Langzeit-Verlauf des Galaktomannan-Antigen im Serum bei invasiver Aspergillose

Christina Linke und Andreas Groll
Pädiatrische Hämatologie und Onkologie




- Nutzen von Galaktomannan als Screening-Parameter bei Kindern durch verschiedene Studien belegt (ECIL-4, SIOP).
- Möglicher Nutzen als Parameter für das Monitoring des Krankheitsverlaufs nicht bekannt.

Patientin 1

- 14 Jahre alt, refräktäre AML, ED 01/11
- Induktionsversagen und eingeschränktes Ansprechen auf experimentelle Therapieversuche mit Clofarabin, Gemtuzumab und Sorafinib
- Erstdiagnose einer pulmonalen invasiven Aspergillose 08/11 vor geplanter Knochenmarktransplantation.


Patientin 1

Galaktomannan




Patientin 1

Galaktomannan




Patientin 1

Galaktomannan




Patientin 1

Galaktomannan




Patientin 1

Galaktomannan




Granulozyten (Anzahl/ μ l)




T-Helferzellen (Anzahl/ μ l)

Patientin 1

Galaktomannan




Granulozyten (Anzahl/ μ l)




Patientin 1

Galaktomannan




Patientin 1

Galaktomannan




Patientin 1

Galaktomannan




Patientin 1

Galaktomannan




Patientin 1

Galaktomannan



Patientin 1

Galaktomannan




Patientin 2

- 13 Jahre alt, MDS vom Typ der refraktären Zytopenie, ED 07/10
- Erstdiagnose einer invasiven pulmonalen Aspergillose an Tag +25 nach erster Knochenmarktransplantation 03/11


Patientin 2

Galaktomannan




Patientin 2

Galaktomannan




Patientin 2

Galaktomannan




Patientin 2

Galaktomannan



Patientin 2

Galaktomannan



Granulozyten (Anzahl/ μ l)

4.000

3.000

2.000

1.000

0

Mrz Apr Mai Jun Jul Aug Sep Okt Nov Dez Jan Feb Mrz Apr Mai Jun Jul Aug Sep

T-Helferzellen (Anzahl/ μ l)

400

300

200


100

0


Mrz Apr Mai Jun Jul Aug Sep

Patientin 2

Galaktomannan




Granulozyten (Anzahl/ μ l)




Patientin 2

Galaktomannan




Granulozyten (Anzahl/ μ l)




Patientin 2

Galaktomannan




Patientin 2

Galaktomannan




Patientin 2

Galaktomannan




Galaktomannan

22.08.2011




Patientin 2

Galaktomannan




Patientin 2

Galaktomannan




Patientin 2

Galaktomannan




Patientin 2

Galaktomannan



Patientin 2

Galaktomannan



- Eingeschränkter Nutzen für das Monitoring von Krankheitsverlauf und Therapieansprechen.
- Viele schwer berechenbare Einflussfaktoren durch Immunsuppression und multiple Komorbiditäten.
- Galaktomannan lässt sich nur in Zusammenschau mit klinischen und bildgebenden Befunden bewerten und kann nicht ausschlaggebend für Therapieentscheidungen sein.